Form D · Biotechnology
Gibson Oncology, LLC
Miami, FL · CIK 0002042777
Offering snapshot reported Jul 21, 2025 · SEC filing
- Reported sold
- $250K Offering amount: $1.5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 7, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 21, 2025 | Initial | $250,000 | No comparison | 1 | SEC filing |
| Oct 31, 2024 | Initial | $3,800,000 | No comparison | 8 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-552293
Source: Form D, filed Jul 21, 2025. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mark Baganz | Director |
| Mark Cushman | Director |
| Randall Riggs | Director, Executive |
| Elizabeth Rogers | Director, Executive |
| Mark Rogers | Director |
| Clifford Solomon | Director, Executive |
| Theodore Solomon | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
7772 Fisher Island Drive
Miami, FL, 33109
Miami, FL, 33109